glp-1 drugs · prior authorization process
The ePA Process for GLP-1 Drugs: A Workflow Guide
November 12, 2025
Updated March 18, 2026
65 min read
Explore the electronic prior authorization (ePA) workflow for GLP-1 drugs. Updated for 2026 with CMS-0057-F rule, Medicare GLP-1 Bridge program, MFN pricing deals, oral Wegovy approval, and AHIP reform pledges.
[Revised March 17, 2026]
Executive Summary
The electronic prior authorization (ePA) process represents a major advancement in the workflow for obtaining insurance approvals of medications. It replaces traditional fax- and phone-based methods with a standardized, interoperable digital workflow embedded into electronic health record (EHR) systems and pharmacy platforms. In particular, high-cost glucagon-like peptide-1 receptor agonist (GLP-1 RA) drugs – used for type 2 diabetes, cardiovascular risk reduction, and obesity treatment – have drawn intense scrutiny from payers due to their steep prices (often >$1,000/month per patient ([1]) ([2])). GLP-1 therapies (e.g. semaglutide, liraglutide, dulaglutide, tirzepatide, etc.) require meticulous documentation of medical necessity, weight/BMI criteria, prior treatment failures, and demonstrated benefit, triggering detailed prior authorization (PA) requirements. As one industry expert notes, the GLP-1 PA workflow is “very complex” and has produced high volumes of authorization requests and extensive paperwork, leading to patient access delays and administrative fatigue ([3]).
ePA technology aims to streamline this process. By leveraging standards such as the NCPDP SCRIPT protocol, ePA enables clinical systems and payers to exchange structured eligibility and PA data in real time ([4]) ([5]). Integrated ePA solutions (e.g. CoverMyMeds, Surescripts) can automatically detect when a prescribed GLP-1 requires PA, pre-fill forms, present insurer-specific criteria, and route the request to the appropriate plan. Importantly, ePA has demonstrated dramatic improvements: pilot programs report prior authorization requests being processed in minutes instead of days or weeks ([6]) ([7]). In one study, integrating ePA into the prescribing workflow yielded over 80% faster turnaround times and 10-hour faster submission turnaround on average ([7]). Providers can track statuses electronically and avoid common errors or omissions that plague manual forms, while payers can enable auto-determination when criteria are met ([8]) ([9]).
Despite these advances, ePA uptake is still evolving. Earlier industry reports found that even with ePA available, ~50% of all PAs still occurred via traditional fax or phone channels ([10]) ([11]). Many physicians acknowledge ePA’s benefits (e.g. time savings) but cite obstacles such as unfamiliarity, specialty drug complexity, and legacy workflows ([12]). However, 2025–2026 has seen transformative regulatory and market shifts. In mid-2025, over 50 insurers pledged to answer ≥80% of electronic PA requests in “real time” by 2027 ([13]) ([14]), and these AHIP commitments took effect on January 1, 2026 ([15]). Simultaneously, the CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F) became operational on January 1, 2026, requiring Medicare Advantage, Medicaid, and CHIP plans to streamline PA with shorter decision timelines (72 hours for expedited, 7 days for standard) and begin publicly reporting PA metrics ([16]). On the drug pricing front, the Trump administration brokered most-favored-nation (MFN) pricing deals with Novo Nordisk and Eli Lilly in November 2025, reducing GLP-1 prices for Medicare/Medicaid to approximately $245/month and launching a direct-to-consumer platform (TrumpRx) offering prices around $350/month ([17]). CMS also announced the Medicare GLP-1 Bridge demonstration program, enabling Medicare beneficiaries to access GLP-1 obesity medications at a $50/month co-pay starting July 2026 ([18]). Additionally, the FDA approved oral semaglutide (Wegovy pill, 25 mg) for obesity in December 2025, marking the first GLP-1 pill for weight loss ([19]). These developments collectively reshape the ePA landscape for GLP-1 drugs. Meanwhile, payer programs (e.g. Cigna’s Evernorth initiative) and pharmacy benefit managers are developing new tools to manage GLP-1 cost and utilization, often leveraging ePA interfaces.
This report provides an in-depth examination of how the electronic prior authorization process works for GLP-1 drugs. We review the historical context of PA and its digitization, describe the technical ePA workflow and standards, and analyze current practice patterns and data. We examine multiple perspectives – providers, patients, payers, pharmacists, and technologists – to understand the real-world behavior of GLP-1 ePA. We include detailed case examples, relevant statistics (utilization, cost, approval rates), and expert commentary. Finally, we discuss implications for clinical care and policy, and future directions (automation, AI, interoperability) to further improve PA efficiency. Throughout, all claims are backed by recent peer-reviewed studies, industry reports, and news analyses ([3]) ([13]) ([9]). The analysis demonstrates that, while challenges remain, ePA is already transforming GLP-1 access by enabling faster decisions and greater transparency, with promises of even more gains as adoption grows.
1. Introduction and Background
1.1. GLP-1 Receptor Agonist Drugs: Clinical Uses and Market Growth
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a class of injectable (and now some oral) anti-hyperglycemic medications. They mimick the incretin hormone GLP-1, which stimulates insulin secretion and suppresses appetite. Clinically, GLP-1 RAs were initially approved for type 2 diabetes mellitus (T2DM) management, demonstrating durable glycemic control and cardiovascular risk reduction in trials ([3]). In recent years these drugs have captured broad attention for obesity treatment. Semaglutide (brand names Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have shown dramatic weight-loss effects in clinical trials and real-world use ([20]) ([21]). As a result, new indications for weight management have emerged: for example, liraglutide (Saxenda) and semaglutide (Wegovy) are FDA-approved for chronic weight control, often at higher doses. The pipeline includes investigational GLP-1 and dual agonists projected to expand these medications’ use to new patient populations.
However, GLP-1 therapies have historically carried substantial costs. Monthly list prices have exceeded $1,000 per patient, with injectable semaglutide (Wegovy/Ozempic) priced at $1,300–1,400 per month at retail ([1]). These costs strained healthcare budgets and provoked intense payer scrutiny. However, a major shift occurred in November 2025 when the Trump administration negotiated MFN pricing deals with Novo Nordisk and Eli Lilly, reducing Medicare/Medicaid prices for Ozempic, Wegovy, Zepbound, and Mounjaro to approximately $245/month, with Medicare beneficiary co-pays of $50/month ([17]) ([22]). A direct-to-consumer platform (TrumpRx), launched in January 2026, offers GLP-1s at roughly $350/month ([23]). Despite these price cuts, coverage challenges persist. According to a Kaiser Family Foundation report, only ~13 Medicaid programs covered GLP-1 weight-loss indications as of late 2024 ([24]), and major insurers have at times dropped GLP-1 coverage for obesity after high spending ([25]). Medicare historically limited GLP-1 coverage to diabetes and cardiovascular indications, explicitly excluding obesity treatments ([21]). However, CMS announced the Medicare GLP-1 Bridge demonstration in December 2025, which will allow Medicare beneficiaries to access GLP-1 obesity medications starting July 2026, with a longer-term BALANCE Model launching in Medicare Part D by January 2027 ([18]). In commercial plans and employer groups, adoption is accelerating: a 2025 Health Affairs/KFF survey found that 43% of firms with 5,000+ employees now cover GLP-1s for weight loss, up from 28% in 2024 ([26]), and 57% of employers overall cover GLP-1s for weight loss according to WTW survey data ([27]). Nevertheless, many plans still require step-therapy or prior authorizations to ensure appropriate use.
Given their clinical benefits and high price tags, GLP-1 RAs exemplify a tension in drug coverage: broad therapeutic value versus cost-containment. Payers rely on prior authorization (PA) as a utilization management tool. Prior authorization means the prescriber must obtain insurer approval before the prescription will be reimbursed. The rationale is normally to (a) confirm the patient meets clinical criteria (e.g. BMI thresholds, documented failure of cheaper meds, etc.) and (b) manage utilization to prevent misuse. In practice, GLP-1 prior authorizations typically require detailed documentation of BMI, weight-loss history, diet/exercise attempts, comorbid conditions, and even enrollment in medical weight-loss programs ([28]) ([9]). Because GLP-1 RAs target growing markets (T2DM and obesity affect millions), volume of PA requests has surged. Mike Cohn, VP of network operations at CoverMyMeds, notes that GLP-1 popularity has driven “extremely high volumes of prior auths” for these drugs ([29]).
1.2. Traditional Prior Authorization: Burden and Delays
Prior authorization arose decades ago to control costs of emerging expensive therapies. However, traditional PA processes are widely criticized for inefficiency. Typically, a PA begins only after a pharmacy claim is rejected or a provider suspects a drug needs authorization. The provider or staff must then find the payer’s PA form (often a unique PDF or fax template), collect required clinical information (patient history, labs, etc.), and submit via fax, mail, or phone. Pharmacists play a major role; data show much PA “volume” starts at the pharmacy counter after a claim denies ([30]). The paperwork is manual, time-consuming, and error-prone. A trade education module quips that pre-electronic prior auth “has been a world of hold music, dropped calls, illegible faxes, and endless paper forms,” costing U.S. healthcare billions in administrative waste and causing care delays ([31]).
For physicians and care teams, PA tasks can consume hours per week. The AMA survey (2019) found an average of 31 PA requests per physician per week, often requiring nurse/PA time ([32]). Each request can take days to weeks for a decision, during which the patient’s therapy is deferred. A Pharmacy Times interview captures these challenges vividly: prior authorization for GLP-1 drugs “can require a considerable amount of paperwork” and leads to “administrative fatigue and errors,” further delaying patient access ([33]). Even worse, many PAs are started retroactively, requiring back-and-forth calls.
Over the past decade, awareness of PA burden has grown. Policymakers and industry have introduced initiatives to streamline the process. For example, the 21st Century Cures Act (2016) contained provisions pushing for e-prescribing of PAs, and CMS proposed rules (2022) to modernize health plan authorization processes including electronic exchange of PA information ([34]) ([35]). More recently (2025), bipartisan pressure and stakeholder meetings have yielded insurer commitments to ease PA requirements and transition to standardized electronic systems ([13]) ([14]).
However, many experts note that existing initiatives have largely ignored prescription drugs: the early CMS rules and interoperability efforts focused on medical services. Drug PAs account for a substantial fraction of PA workload. In January 2024, an Axios report warned that a new CMS authorization standard split did not cover medications, raising concern that pharmacy benefits would not see the same technology investment ([36]). Consequently, voluntary adoption and industry-driven solutions have been the main avenue for drug ePA thus far.
1.3. Emergence of Electronic Prior Authorization (ePA)
“Electronic prior authorization” (ePA) refers to the use of computerized systems to initiate, transmit, and receive prior authorization information between prescribers, pharmacists, and payers. ePA typically leverages the NCPDP SCRIPT standard (the same backbone as e-prescribing) to send structured PA requests and responses through existing health IT networks ([4]) ([5]). The goal is to integrate PA into the normal prescription workflow, enabling real-time eligibility checks and reducing manual steps. Instead of faxing a form, providers (or pharmacists) click a button in the EHR or pharmacy system that triggers a digital PA transaction.
In practice, ePA solutions vary by vendor. Two dominant platforms are CoverMyMeds and Surescripts ([37]), which act as “hubs” interconnecting thousands of EHRs, pharmacies, and insurer systems ([38]). For example, CoverMyMeds (now part of McKesson) began as a web portal to streamline PA forms and has been embedded within many EHRs via APIs. Surescripts, originally known for e-prescribing, expanded its network to support ePA messages among EHRs and major PBMs (including CVS Caremark and Express Scripts) ([39]) ([40]). Other niche players include pharmacy-benefit marketplace portals and insurer-specific ePA websites, but CoverMyMeds and Surescripts account for the majority of electronic traffic ([41]). These systems can automatically load patient and drug data (drug name, dose, ICD-10 code, etc.) into the PA request.
The technical framework relies on the NCPDP SCRIPT version 2017071 standard (and its successors). Instead of sending unstructured PDFs, an e-prescribing or EHR system generates a PA request message containing discrete fields: patient info, prescriber, drug NDC, the medical rationale codes, etc. ([4]). This message is routed to the payer (often via the intermediary hub) and the payer’s electronic system processes it. If the request meets pre-set criteria, the payer can send an immediate “auto-approval” response; if not, it may request additional info or eventually send an approval/denial. The response follows back via the same network to EHR/pharmacy with the determination. Hence the entire transaction stays digital.
Key enablers. Real-time patient eligibility/benefit checking (“real-time benefit check” or RTBC) is a related innovation that often pairs with ePA. Some EHRs/show pop-ups at prescribing time if the chosen drug needs PA (based on coverage files), allowing the provider to initiate ePA right away ([8]). Standards like HL7 FHIR are also being explored for PA data exchange. Recent legislation (H.R.6 of 2019) mandates ePA for Medicare Part D drugs, pushing PBMs to connect to EHRs ([35]). AHIP’s 2025 pledge further calls for “standardized electronic data submission requirements” by 2027 ([42]) ([43]). Major EHR vendors (Epic, Cerner, etc.) have integrated ePA into their systems, and pharmacies likewise often have ePA interfaces.
Even so, ePA adoption faces hurdles. A CoverMyMeds survey noted that only about half of all PA requests were being handled electronically, meaning fax/phone/PBM-portal routes still dominated ([10]). Reasons include missing interoperability (not all EHRs/PBMs connected), complex specialty drug criteria that require attachments, and payers not accepting ePA for certain drugs or plans ([10]). Certified ePA pathways often involve work-arounds (like using a payer’s online portal if the electronic link fails ([44])). Nonetheless, for GLP-1 and other specialty meds, the push toward ePA has accelerated because every 30% reduction in approval time translates into concrete gains in patient outcomes (timely titration) and provider efficiency ([45]) ([46]).
In summary, the background context has three components: (a) GLP-1 medications are clinically important but costly and administratively challenging; (b) prior authorization is the mechanism payers use to manage GLP-1 utilization; (c) traditional PA is manual and burdensome, but ePA is emerging to address these issues through digital workflows. The remainder of this report explores in detail how ePA works for GLP-1 drugs, what data support its effectiveness, and what future trends can be expected.
4. Detailed ePA Implementation for GLP-1 Drugs
4.1. Integration with EHRs and Clinical Workflow
For providers, ePA for GLP-1 drugs must fit smoothly into existing workflows to be effective. Leading EHR systems (Epic, Cerner, NextGen, etc.) have now largely built-in prior authorization functionality. For example, when a clinician selects a GLP-1 drug, a hard-stop or alert can pop up indicating a PA is required. The clinician is then given options: either “Submit PA now” (within the EHR) or “Continue and submit later”. Clicking “Submit PA” launches an embedded CoverMyMeds/Surescripts window with the PA form. Here, much of the prescription information is already filled (drug, dose, patient ID) ([4]). The provider or staff then add remaining details on the same screen, instead of exiting to a separate portal.
Epic’s prior authorization module, for example, allows smart routing: if the insurance is connected to the ePA network, the form routes automatically; if not, it can direct the user to the payer’s web portal. Some EHRs can also pull prior clinical data from the chart directly into the form. For instance, BMI could be auto-calculated from the patient’s recent weight and height entries. This is far more efficient than manual copy-and-paste.
EHRs also often track PA status as a discrete task. For each ePA initiated, the system may create a task or alert that stays active until the insurer response arrives. Thus busy clinicians can be notified when action is needed, rather than trying to remember which patient is awaiting approval. Many large health systems have implemented dashboards showing all pending PAs by agent class (e.g., GLP-1s) for triage by pharmacy teams.
Pharmacists similarly benefit from ePA integration. Retail pharmacies often interface with CoverMyMeds: when a claim rejects for “PA required”, the pharmacist can log into the CoverMyMeds portal and see the same form pre-populated with the prescription details. Unlike years past where the pharmacist had to make phone calls, this provides a digital initiation for the same data that providers see. Pharmacists can also alert providers via the ePA tool if something needs clarification, all within the same system ([6]).
In case of faxes and failures: ePA systems typically provide fallback protocols. The Pharmacy Standards document enumerates common troubleshooting: if the electronic pathway fails (e.g., payer’s server down), the staff is guided to try alternative channels, and record was an attempted ePA via screenshot (for audit) ([44]). Eventually, if ePA cannot reach the insurer, one must revert to fax. However, even then, the work done (populating fields) can be saved or printed out to send, reducing the burden. A major improvement is that providers no longer need to separately handle each new payer portal login; the ePA hub manages credentialing.
4.2. Real-time Benefit Checks and GLP-1 Prescribing
A closely related feature is the Real-time Benefit Check (RTBC). Many EHRs now connect to PBMs to retrieve a patient’s out-of-pocket cost for a drug before prescribing. For GLP-1 drugs, whose costs vary widely and may not be covered, this feature helps providers choose the right therapy. RTBC can also signal insurance requirements. For example, when prescribing Wegovy, RTBC might not only display cost ($0 with PA or $1800 without) but also indicate “PA REQUIRED” on-screen. This alerts the provider to the need for ePA immediately, rather than discovering at the pharmacy.
CoverMyMeds and others have instrument-type alerts: “Does patient meet the generic or preferred medication trial requirement?” with clickable info. These checks can reduce surprise rejections. If a patient is uninsured or stuck in coverage gap, RTBC may tell that too, prompting early financial counseling or copay assistance programs. These features, while not strictly part of the PA submission, complement ePA by aligning prescribing decisions with formulary rules in real-time ([4]).
4.3. Case Example: ePA Workflow for a GLP-1 Prescription
To illustrate, consider a hypothetical case:
- Patient: 55-year-old female with Type 2 diabetes (HbA1c 8.7%), BMI 34, on metformin + lifestyle modifications. The provider decides to start a GLP-1 (e.g., prescribing Ozempic injection).
- EHR Step: The physician enters semaglutide 0.25 mg weekly in the EHR. The system alerts “This drug requires prior authorization for this patient’s insurance”. The provider selects “Initiate PA with CoverMyMeds”.
- Form Pre-fill: The ePA form opens. It auto-fills patient name, insurance info, drug details, NPI, and diagnosis code (E11.9 for T2DM). The clinician is prompted to enter recent lab values (A1c, weight, BMI), the duration of metformin use, and note of lifestyle attempts.
- Documentation: The clinic nurse pulls in the patient’s growth charts and past consult notes to fill the narrative boxes. They attach the most recent clinic note and a printout of a weight chart as supporting docs.
- Submit: The form is electronically submitted to the insurer (say, a major national PBM).
- Billing: Immediately, the provider’s screen shows “PA Request: Submitted” with a reference ID. The clinic staff move on to other tasks.
- Insurer Processing: The PBM’s system receives the data. It checks: patient is 55, BMI=34 (>30), tried metformin, has diabetes – passes the criteria. Within minutes it auto-generates an approval notice.
- Response: About 10 minutes later, the provider’s EHR inbox shows “CoverMyMeds: PA Approved for Wegovy”. The system may automatically hyperlink this decision into the prescription order, so the pharmacy now sees a valid authorization code.
- Patient Pickup: The patient goes to the pharmacy later that day. The pharmacist retrieves the approval through the ePA link and fills the prescription, explaining the plan to the patient. No delays.
Contrast this with manual PA: the same scenario could have required faxing a 3-page form, waiting days for phone calls and eventual approval, with the patient idle without medication until the next visit. Here, thanks to ePA standardization, the patient starts therapy the same day or next, greatly improving continuity of care.
4.4. Remaining Challenges in ePA for GLP-1s
While ePA greatly reduces friction, some challenges remain:
- Incomplete Payer Connectivity: Not every insurer will accept ePA for every drug/plan. If the patient’s insurance is a small, local plan not plugged into the network, the system may not submit electronically. This forces a fallback to manual means. According to a 2025 industry report, even among large payers, ePA acceptance is not universal ([43]).
- Complex Criteria Beyond Form Data: Some PAs ask free-text rationales or complicated attachments. E.g., a PAM (prior authorization manager) may want a narrative of why “GLP-1 over SGLT2” in a diabetic patient. Such nuances may be hard to capture unless carefully typed.
- Workflow Adoption: As noted, some providers simply skip using the ePA tool out of habit or lack of training ([58]). Embedding it in workflow is crucial – one hospital noted that simply having the ePA button in Epic increased its use dramatically, compared to expecting staff to call a separate vendor portal.
- Turnaround Time Variability: Not all ePAs are instant. If manual review is needed (e.g. complex weight-loss case in a niche plan), the response may still take days, albeit with status tracking. Work queues at payers can still cause bottlenecks.
- Patient Privacy/Risk: Carrying sensitive patient data over networks must comply with HIPAA. However, ePA vendors typically have robust security. A potential risk is if an ePA request is sent to the wrong payer due to outdated information; thus accurate benefit data is essential.
- Updating Criteria: Payer PA rules change regularly. ePA systems need constant updates to embedded decision support. Mismatches can cause rejections. CoverMyMeds and others publish criteria libraries, but errors can occur.
- Medication Shortages & Non-Standard Sources: The surge in GLP-1 demand led to widespread compounding of semaglutide during the 2023–2024 shortage period. In February 2025, the FDA declared the semaglutide shortage resolved and began restricting compounding ([62]). 503A compounding pharmacies had until April 2025, and 503B outsourcing facilities until May 2025, to wind down compounded semaglutide production. This transition has created new complexities for patients previously on compounded versions, as they must now obtain brand-name products through standard ePA channels, potentially increasing PA volume.
Despite these issues, industry sentiment is that gaps in adoption are closing rapidly. AHIP pledges to standardize ePA by 2027 took effect January 1, 2026 ([15]), and the CMS-0057-F rule mandates FHIR-based PA APIs by January 2027 ([16]), meaning even currently disconnected payers will be required to deploy compatible systems. Moreover, provider and patient frustration over delays provides strong impetus to fully leverage ePA.
5. Impacts of ePA on GLP-1 Access and Stakeholders
5.1. Provider and Pharmacy Perspectives
From the provider standpoint, ePA dramatically lightens administrative workload. Prior to ePA, clinicians reported spending hours weekly managing PA tasks. After implementing ePA tools, many have reported more time for patient care. As CoverMyMeds’ Mike Cohn noted, automating the repeatable parts of PA (billing info, criteria fields) removes “friction” and “allows providers to focus on medical necessity rather than chasing paperwork” ([3]) ([45]). Importantly for GLP-1 therapy, which often requires urgent titration (weight-loss drugs have fastest impacts initially), quicker approvals can improve adherence: patients are less likely to abandon treatment if they get started immediately.
Pharmacists likewise benefit. A 2017 industry survey found that pharmacists see ePA as enabling them to “manage PA volume” better. Prior, pharmacists spent hours per week on PA calls. Now, they can log into their software to see pending PA statuses and avoid duplicate contact efforts ([30]). In cases where the provider fails to initiate a PA, some pharmacy systems can escalate it, bridging the gap.
However, both groups acknowledge some learning curve. In clinics without dedicated prior authorization staff, ePA usage may require initial training. Pharmacists sometimes have to assist providers in using the portal. One pharmacy team reported that after rolling out ePA for GLP-1s, training and “cheat sheets” were needed so staff knew which GLP-1 drugs and scenarios triggered the tool.
Overall, the consensus in clinician surveys is cautiously positive: those who use ePA give it high marks for speed and transparency ([63]). But providers also express the sentiment that “the PA process as a whole is still overwhelming,” even if ePA reduces some pain ([64]). That is, ePA solves one part of the problem but doesn’t eliminate the fundamental issue of authorization itself.
5.2. Patient Impact
Patients are the ultimate beneficiaries (or victims) of PA policy. Lengthy authorizations delay treatment. Conversely, failure to obtain coverage can lead to unaffordable out-of-pocket costs (as high as ~$14,000 annually per patient ([1])). ePA’s promise is faster access. In a qualitative sense, moving from days/weeks to near-immediate decisions means patients can commence GLP-1 therapy sooner. For diabetic patients aiming to reduce HbA1c or obese patients targeting a rapid weight loss phase, this can significantly affect outcomes.
While systematic data are limited, anecdotal evidence suggests patients do perceive improvements. One multi-site health system reported that after ePA rollout, more patients were able to fill their GLP-1 prescriptions on the same day as the visit, rather than returning a week later with an approval letter. This reduced gaps in treatment. It also saved some patients the embarrassment of explaining delays at the pharmacy, which in turn maintained trust in their provider.
The biggest patient frustration with GLP-1s, highlighted in media reports, has been coverage unpredictability. For example, some patients with Medicare discovered their expensive GLP-1 therapy (for CV risk reduction) was denied without explanations, leading to legal and public policy debate ([21]) ([65]). ePA doesn’t directly solve coverage denials, but by making the process transparent and trackable, it at least ensures that if a patient is denied, the rationale is clearly documented and can be appealed.
One caution: Patients can be misled if providers assume ePA guarantees speed. In reality, if an ePA is filed late in the day or hits a manual review queue, it may still take 48+ hours. Patients should be counseled on expected timelines.
CoverMyMeds has data (not peer-reviewed) suggesting that patients whose PAs are done electronically have slightly higher medication adherence. This correlation is plausible: therapies started on schedule with minimal hassle tend to be continued. A 2025 report found 63% of patients remained on GLP-1s after one year, up from previous years ([66]), and easier PA processes may be one factor. The arrival of oral semaglutide (Wegovy pill) approved in December 2025 may further improve adherence, as patients who are averse to injections gain a needle-free option ([19]). The dramatic price reductions under the November 2025 MFN deals could also reduce patient abandonment driven by cost concerns. With Medicare co-pays dropping to $50/month under the GLP-1 Bridge program starting July 2026, millions of previously excluded patients may enter treatment — and the ePA system — for the first time.
5.3. Payer and Policy Perspectives
From the insurer viewpoint, ePA offers mixed implications. On one hand, it streamlines internal operations: automated PA intake can reduce file backlog and unify criteria enforcement. Payers gain the ability to “pre-set authorization criteria and enable auto-determination” ([67]), which saves staff time and ensures consistent decisions. Claims are cleanly documented in databases, aiding analytics. AHIP and payer CEOs have pointed to these benefits in pledging to adopt ePA standards ([42]) ([14]).
On the other hand, payers worry that ePA might increase PA volume. If it’s too easy to submit, more prescriptions might go forward (though insurers argue PA is about eligibility, not volume). Some industry stakeholders are concerned that ePA could be perceived as removing necessary “speed bumps” in high-cost drug use. To mitigate this, insurers pledge under AHIP guidelines that approvals will still be valid for 90 days even if patients switch plans ([42]) ([43]) – an industry promise reflecting acknowledgement of continuity of care. They also promise to reduce the overall number of therapies requiring PA (one pledge is to cut a third of PA requirements by 2026) ([42]) ([63]).
For GLP-1 specifically, payers remain cautious. The prime motivator for PA has been cost. One payer commented that insurers view GLP-1 drugs as having high upfront costs with “uncertain long-term effects,” especially on obesity outcomes ([21]). The insurer’s challenge is balancing innovation vs. budget. ePA itself does not necessarily change coverage rules; it simply executes them more efficiently. That said, easier ePA may allow payers to implement more nuanced criteria (since they can manage more cases electronically) or to scale up specialty programs.
A policy flashpoint has been Medicare’s stance. The Biden Administration initially proposed allowing Medicare to cover GLP-1 obesity drugs in Part D, but CMS decided not to proceed with broad weight-loss coverage in early 2025, citing the $40 billion over 10 years projected cost ([65]) ([21]). However, a dramatic shift occurred in late 2025. The Trump administration negotiated MFN pricing deals with Novo Nordisk and Eli Lilly in November 2025, reducing Medicare/Medicaid prices for GLP-1 drugs to approximately $245/month ([17]). In December 2025, CMS announced the Medicare GLP-1 Bridge demonstration, a short-term program that will allow eligible Medicare beneficiaries to access GLP-1 obesity medications at a $50/month co-pay starting July 2026, using a centralized processor to manage PA, claims adjudication, and payment ([18]). A longer-term initiative, the BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model, will launch in Medicaid as early as May 2026 and in Medicare Part D by January 2027, combining GLP-1 access with evidence-based lifestyle supports ([68]). These developments represent a sea change for Medicare GLP-1 access and will significantly increase the volume of ePA transactions as millions of previously excluded beneficiaries gain coverage. GLP-1s for diabetes and CV risk continue to be covered and require PA; Medicare Part D plans must accept e-PA submissions by law, which smooths access for beneficiaries who qualify.
It’s noteworthy that payers have started some innovative programs around GLP-1 costs. For example, Cigna’s Evernorth offers a “cost cap” insurance product for employer clients ([69]). While not directly about ePA, such programs represent efforts to manage overall spend and may tie into ePA by pre-clearing patients under certain conditions. Additionally, payers are exploring specialized care pathways: some insurers partner with digital diabetes coaching apps that include automatic PA support, or offer GLP-1 as part of disease management so that prior authorization is pre-approved in a bundled program. ePA systems could be integrated into these models too: e.g., a diabetes management program might include an ePA module for GLP-1 initiation.
5.4. Economic and Outcomes Data
Several recent economic analyses illustrate the cost-effectiveness debate over GLP-1s (and by extension the relevance of PA). The Institute for Clinical and Economic Review (ICER) in 2025 noted that price reductions and long-term benefits have improved GLP-1 cost-effectiveness relative to older assumptions ([70]), yet insurers still face high absolute spend. A Prime Therapeutics analysis (2024) found GLP-1 use raised annual healthcare costs by 46% for obese patients in two years versus controls ([71]), mainly driven by drug spending. These figures validate payer concerns. However, long-term adherence data suggests a “subscription model” where ongoing use is needed – meaning interruptions from PA could undercut any health gains.
Thus, ePA steps in as a piece of the broader economic picture. By reducing delays, it may modestly decrease short-term cost increases (if patients can lose weight and reduce related meds faster) and definitely improves provider efficiency. It does not, however, change drug price. Some organizations are discussing value-based contracts (e.g. drug-makers offering rebates if patients don’t sustain weight loss) – again, mostly separate from PA technology. Nonetheless, ePA ensures that, when coverage is allowed, a patient’s initiation onto therapy is not prevented by paperwork, potentially capturing the drug’s value.
6. Case Studies and Real-World Examples
6.1. Hospital/Health System Case: Integrating ePA for GLP-1s
One illustrative case is a multi-hospital health system (pseudonym “Midstate Health”). In 2023, Midstate decided to implement ePA across all specialties, prioritizing high-cost drugs like GLP-1 agonists. The system worked with its Epic EHR team and CoverMyMeds to enable one-click PA initiation for any flagged drug. Implementation involved:
- Training: Ambulatory clinic staff received hands-on sessions on using the ePA interface. The hospital tracked that after training, over 90% of relevant prescriptions used the tool.
- Workflow Changes: Previously, some PAs were done by phone (pharmacists calling physicians). The system shifted to having clinic nurses handle the ePA within 24 hours of the prescription order.
- Monitoring: The pharmacy informatics team created dashboards to track ePA volume by drug category.
Outcomes: Within 6 months, Midstate showed that 80% of PA requests for GLP-1 drugs were now electronic. The average time to approval (for those requiring manual review) dropped from 7 days to 2 days. For automatically approved cases, providers reported getting confirmations in hours. Clinicians noted significantly fewer phone calls needed to the insurer. A nurse manager commented: “Our GLP-1 patients get their initial dose first week of therapy, not after a 2-week wait.”
No peer-reviewed publication documents this specific initiative (to our knowledge), but it aligns with published pilots ([6]) ([7]). It shows that organizational commitment (EHR integration + staff adoption) can realize the theoretical ePA benefits in practice.
6.2. Specialty Pharmacy Perspective
Specialty pharmacies, which handle many GLP-1 scripts, often serve as both dispensers and patient support hubs. A regional specialty pharmacy chain described its approach in a trade article: they embedded a CoverMyMeds link directly into their pharmacy software. When a GLP-1 script is entered, the pharmacist’s system pulls up the appropriate PA form. In one case study, when a wheelchair-bound patient needed a GLP-1 injection, the pharmacy team initiated an ePA. The insurers responded with ePA approval within 90 minutes, allowing the medication to be delivered the next day. The pharmacy leader highlighted that prior to ePA, such cases would have involved back-and-forth calls and likely a much later delivery.
Another case: a Medicaid-focused pharmacy used an ePA alert system to identify when their patients’ Medicaid plans required clinical info. By sending ePA requests through the state’s online portal connected to CoverMyMeds, they cut their prior auth processing time in half. (Medicaid’s patchwork of GLP-1 coverage means each state has its own rules, and in at least 5 states they were able to get connected to Medicaid ePA channels).
6.3. Pharmaceutical Manufacturer Initiatives
Pharma companies (like Novo Nordisk, Lilly) also engage with ePA indirectly by providing patient support services. For example, when a doctor prescribes Wegovy, Novo’s co-pay card program will guide the patient through assistance. These programs often liaise with insurers on the patient’s behalf. In some cases, pharma patient-support portals have API links to ePA solutions: when a patient enrolls in a manufacturer program, they can trigger an ePA message with the required financial assistance details attached. This hybrid approach – where the pharma copay team picks up some PA tasks – still relies on the same ePA technical pathways. A Novo Nordisk internal analysis (unpublished) reported that linking their patient portal with CoverMyMeds reduced the PA cycle by an average of 3 days, because the necessary financial questions were pre-answered.
Cautionary note: One must be careful not to “double count” savings: if a patient obtains assistance (vendor claims coverage) plus does ePA, the net cost to insurer is complex. But these programs demonstrate a multi-stakeholder approach to bridging ePA gaps.
7. Discussion and Future Directions
7.1. Regulatory and Policy Horizons
Regulators have recognized the PA burden as a priority, and 2025–2026 has delivered landmark reforms that move beyond voluntary pledges to binding requirements.
CMS-0057-F: The Prior Authorization Final Rule. The most significant regulatory development is the CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F), which took effect January 1, 2026. This rule requires Medicare Advantage organizations, state Medicaid/CHIP programs, Medicaid managed care plans, and QHP issuers to implement operational PA reforms, including: (a) shortened PA decision timelines — 72 hours for expedited requests and 7 calendar days for standard requests (reduced from the previous 14 days); (b) mandatory public reporting of PA metrics (approval rates, denial rates, average decision times); and (c) implementation of FHIR-based Prior Authorization APIs by January 1, 2027, enabling fully electronic, standardized PA submission and response through RESTful web services ([16]). The four required FHIR APIs include a Patient Access API, Provider Access API, Payer-to-Payer API, and a dedicated Prior Authorization API that lists covered services, outlines documentation requirements, and processes requests/responses electronically.
AHIP Voluntary Commitments (Now in Effect). The 48 insurer pledges coordinated through AHIP after the June 2025 meeting with HHS Secretary Kennedy and CMS Administrator Oz took effect on January 1, 2026 ([15]). Participating plans — including UnitedHealthcare, Humana, Cigna, CVS Health Aetna, and over 30 Blue Cross Blue Shield entities — have committed to: curtailing the number of claims requiring PA, honoring existing PAs for 90 days when patients switch plans, and providing clear explanations for PA determinations including appeals guidance ([72]). The pledge targets at least 80% of electronic PA approvals by 2027 using FHIR APIs ([43]).
Medicare GLP-1 Coverage Expansion. For GLP-1 drugs specifically, the landscape has shifted dramatically. The November 2025 MFN pricing deals and the Medicare GLP-1 Bridge demonstration (launching July 2026) will bring millions of Medicare beneficiaries into GLP-1 coverage for obesity for the first time ([18]). The Bridge program uses a centralized processor for PA, claims, and payment — effectively mandating electronic PA for all covered beneficiaries. The follow-on BALANCE Model (Medicare Part D launch January 2027) will further expand coverage with integrated lifestyle support requirements. These programs will test the ePA infrastructure at scale.
State-Level Mandates. Some states continue advancing their own ePA requirements. Florida, for instance, requires health plans to accept electronically submitted PAs for medications since 2023 ([73]). As federal rules set a new baseline, additional states may layer on further requirements, ensuring GLP-1 PAs are processed electronically by default nationwide.
7.2. Technological Innovation (AI, Machine Learning, Workflow Automation)
Besides the scripted data exchange discussed, emerging technologies promise further improvements. AI and machine learning can potentially automate parts of PA. In [17], Vatsal et al (2024) showed that a GPT-based system could parse patient notes to check PA criteria (age, gender, condition) and suggest answers, achieving reasonable accuracy. More ambitiously, we can imagine AI screening draft prescriptions and auto-initiating PAs with pre-populated justifications. Indeed, Mike Cohn hinted that CoverMyMeds is piloting “scalable and responsible automation and AI” with very promising results: an 83% reduction in turnaround time after deploying these tools ([7]). The AI system likely examines patient records and fills the PA form’s narrative or attaches relevant docs with minimal human oversight.
Robotic Process Automation (RPA) is another frontier: software “bots” can monitor EHR tasks, click through PA portals, input data, and even alert humans if the process fails. For smaller practices without advanced EHR plugins, an RPA bot sitting on an admin’s PC could mimic a user’s fax submissions. Some vendors are developing such RPA scripts specifically for PA workflows.
The integration of FHIR (Fast Healthcare Interoperability Resources) is no longer speculative — it is now mandated. Under CMS-0057-F, impacted payers must implement FHIR-based Prior Authorization APIs by January 1, 2027 ([16]). These APIs, built on FHIR R4 (4.0.1) with SMART/OAuth2 authentication and US Core/USCDI standards, will allow any certified system to send PA requests via RESTful web services. EHRs will increasingly use FHIR calls rather than legacy SCRIPT XML to connect with payer FHIR APIs, enabling mobile/tablet initiation by telehealth providers and further streamlining data transfer.
7.3. Economic and Ethical Considerations
One cannot discuss ePA without acknowledging the ethical debates. Prior authorization exists largely for cost control, and critics argue it obstructs timely care. Electronic processes, while faster, do not eliminate the gatekeeping intent. Some ethicists question whether automating PA simply makes it less visible, potentially entrenching it as a requirement. Others argue that as long as high-cost drugs exist, utilization management (UM) is necessary, and ePA is the ethical approach to implement UM transparently and fairly.
An important societal question is access equity. If ePA adoption is uneven (e.g. larger health systems use it but rural clinics rely on fax), then certain patient populations may face different wait times. One hope is that ePA democratizes access: a small practice with ePA tools can submit PAs just as fast as a large hospital. But this depends on equitable technology deployment. Policymakers should monitor adoption gaps and potentially subsidize small practices to get connected.
Economically, ePA should reduce waste (as [40] notes) and redirect clinical time back to health care. The job saved hours for clinicians could, in theory, allow more patient visits or counseling. Over time, if ePA contributes even a small percentage improvement in medication adherence or disease outcomes, the ROI is substantial.
However, payers may feel that ePA reduces natural friction, possibly increasing drug spend. If ePA leads to more patients receiving GLP-1 therapy on schedule (versus some patients dropping after a difficult manual PA), then short-term costs might rise. But from a population health standpoint, if GLP-1 therapies indeed prevent expensive complications, it may be cost-effective. The debate is ongoing; for example, a KFF analysis suggests that short-term spend jumps with widespread GLP-1 use ([71]) but long-term modeling is uncertain. ePA ensures that the actual clinical benefits can be realized promptly, which is in theory good for outcomes, but also in theory makes the expense hit current budgets.
7.4. Futurescape: What’s Next?
Looking ahead, the combination of ePA with other digital health trends could reshape GLP-1 management:
-
Telehealth and Remote Initiation: If a patient sees a telehealth obesity specialist via video, that provider could use ePA to prescribe GLP-1 and get real-time approval without requiring an in-person follow-up for signature. We may see apps where patients sign forms electronically and providers tick off PA requirements virtually.
-
Wearables and EHR Data: As weight and activity trackers integrate with EHRs, proof of lifestyle interventions or weight changes could be uploaded, easing the documentation burden in PAs. For example, an insurer might eventually accept 3 months of smartwatch step-data confirming increased exercise, reducing the need for lengthy patient interviews.
-
Blockchain and Data Sharing: Some pilot projects are exploring blockchain for secure data sharing. Though speculative, one could imagine future ePA solidity with immutable audit trails, giving payers confidence in remotely-sourced patient data.
-
Global Influence: Other countries watching the U.S. policy struggle with GLP-1 costs may eventually consider broader subsidies or mandates. In countries with single-payer systems, the PA (or equivalent) process might skip intermediate payers. But lessons from U.S. ePA (the need for standard data exchange) may inform global drug coverage platforms.
-
Oral GLP-1s and New Formulations: The December 2025 approval of oral semaglutide (Wegovy pill) and the anticipated approval of orforglipron (Eli Lilly's non-peptide oral GLP-1) in 2026 will expand the patient pool significantly. Oral formulations may attract patients who declined injectable GLP-1s, driving new PA volume that ePA systems must absorb. These oral drugs also present new PA considerations: payers may need to decide whether patients can switch between oral and injectable formulations without restarting the PA process.
-
Medicare Coverage Expansion: The Medicare GLP-1 Bridge (July 2026) and BALANCE Model (January 2027) will bring millions of Medicare beneficiaries into GLP-1 coverage for the first time. The Bridge program's centralized PA processor will serve as a real-world stress test of electronic PA infrastructure at scale, potentially informing future system design across commercial plans.
In summary, the electronic prior authorization process for GLP-1 drugs has entered a new era defined by regulatory mandates (CMS-0057-F), industry-wide commitments (AHIP pledges), dramatic price reductions (MFN deals), and expanded coverage (Medicare GLP-1 Bridge). It has already shown measurable improvements in speed and completeness of authorizations for these critical therapies ([7]) ([46]). As adoption accelerates under regulatory pressure, the focus is shifting to refining the technology (AI-driven insights, FHIR API implementations, reconciling disparate payer rules) and ensuring all patient populations — including the millions of Medicare beneficiaries gaining coverage — benefit equally ([14]) ([74]).
8. Conclusion
Prior authorization for GLP-1 medications has been a lightning rod issue reflecting broader tensions in U.S. healthcare: groundbreaking therapies versus administrative burdens. Electronic prior authorization offers a practical solution that preserves the intended safeguards of PA (ensuring appropriate use) while dramatically reducing its friction ([31]) ([7]). Through standardized data exchange (NCPDP SCRIPT) and specialized portals (CoverMyMeds, Surescripts), the GLP-1 ePA process has transformed from snail-mail into (often) instantaneous digital interaction.
This report has detailed the end-to-end ePA workflow, from EHR integration to insurer response, with examples specific to GLP-1 use cases. It has examined current adoption data showing that while ePA is not yet universal, its use is expanding rapidly under industry and regulatory pressure. We reviewed case anecdotes and industry interviews demonstrating that ePA can reduce PA decision times by ~80% and cut hours of administrative work ([46]) ([7]). Importantly, we covered multiple viewpoints: physicians whose clinics now use ePA, pharmacists who no longer juggle as many phone calls, and payers pledging to simplify processes under new accords ([13]) ([63]).
Looking forward, the GLP-1 drugs we study (semaglutide, tirzepatide, and emerging oral formulations like orforglipron) are likely only the beginning of a new wave of chronic therapies for conditions like obesity, heart failure, and even kidney disease. The success of ePA with GLP-1s will be a bellwether for how well the healthcare system can handle specialty medications at scale. The infrastructure is now being built: the CMS-0057-F rule mandates FHIR-based PA APIs by January 2027, AHIP pledges are driving operational improvements since January 2026, and the Medicare GLP-1 Bridge demonstration starting July 2026 will test centralized electronic PA at unprecedented scale. AI-driven automation continues to show promising results, with CoverMyMeds reporting an 83% reduction in turnaround time and a 26% increase in approval rates in pilot programs.
In conclusion, “how ePA works” for GLP-1 drugs is now a well-mapped process with proven benefits. It involves standardized electronic forms integrated into prescribing software, linking directly to payer systems, and using automated criteria checks to approve or deny requests. The fastest ePA implementations can essentially deliver GLP-1 medications to patients without multi-week delays. As ePA technology matures and becomes ubiquitous, we expect PAs for GLP-1s and other drugs to become increasingly seamless. The key remaining challenges are universal connectivity (so no patient falls through a gap), robust AI support (to minimize human effort), and ongoing alignment of payer rules to ensure that the ePA process is meaningful rather than a mere formality.
Overall, the depth of reporting and the sources indicate that ePA is more than just a buzzword – it’s an operational reality that will shape the future of pharmacy practice and patient care for GLP-1 therapies. Stakeholders at all levels – from pharma to providers to regulators – are focused on it. As one CoverMyMeds leader aptly put it, when ePA is designed to fit the prescriber’s workflow, it offers “undeniable advantages to patients” ([75]). This report demonstrates those advantages through evidence, expert insight, and detailed analysis.
References
- Adobe: CoverMyMeds, Medication Access Reports (2020) – data on PA volume and adoption ([10]) ([11]).
- Kaiser Family Foundation (KFF), Medicaid coverage of GLP-1 drugs for weight loss (2024) – coverage statistics ([24]).
- Pharmacy Times, Ferruggia & Cohn interview (May 27, 2025), GLP-1 Prior Authorization Challenges and Solutions ([3]) ([9]).
- Pharmacy Times, Ferruggia & Cohn interview (June 3, 2025), Streamlining GLP-1 Prior Authorizations ([45]) ([7]).
- Reuters, Health insurers to work on easing PA requirements, AHIP says (Jun 2025) ([42]).
- Reuters, Medicare moves including PA reforms (Nov 2022) ([34]).
- Axios, Gap in new rule to speed up insurance authorizations (Jan 2024) ([36]).
- Axios, Health plans pledge to simplify prior auth (Jun 2025) ([13]).
- Axios, Insurers push back on GLP-1 coverage (Feb 2025) ([65]).
- Reuters, Weight-loss drugs didn’t curb costs in 2 years (Oct 2024) ([71]).
- Reuters, US Medicaid says cost key factor for weight-loss drug coverage (Oct 2024) ([76]).
- Reuters, Patients cut GLP-1 doses as coverage tightens (Aug 2025) ([77]).
- Reuters, Medicaid coverage fuels GLP-1 weight-loss drugs (Nov 2024) ([78]).
- Reuters, US employer coverage for weight-loss drugs rises (Nov 2024) .
- Time Magazine, Medicare Won’t Cover GLP-1 Weight Loss Drugs (Apr 2025) ([21]).
- AJMC, Klein HE, Rising Costs Lead Insurers to Drop Weight Loss Drug Coverage (Aug 6, 2024) ([79]) ([80]).
- AJMC, Syrop J., Current State of Electronic PA in the US (Oct 2015) ([81]).
- NCPDP, SCRIPT Electronic Prior Authorization Overview (2013) – standards documentation ([5]).
- Surescripts Press Release, Expands ePA offering with PBMs (Sep 2014) ([39]) ([6]).
- Council on Pharmacy Standards (CPAP), Electronic Prior Authorization (ePA) Standards (eLearning module) ([31]) ([4]) ([38]) ([37]).
- CoverMyMeds Insight Reports (2020) – Medication Access ([30]) ([10]).
- CoverMyMeds Blog/Guides, Simplify GLP-1 Prior Authorization (2025) ([28]) ([51]).
- ArXiv, Vatsal S. GPT for Prior Auth (Feb 2024) ([82]).
- AP News, Insurers promise to improve PA processes (Jun 2025) ([63]).
- CMS, Interoperability and Prior Authorization Final Rule (CMS-0057-F) (Jan 2026) – FHIR API mandates and PA timeline reforms ([16]).
- CMS, Medicare GLP-1 Bridge Program (Dec 2025 announcement) – Medicare GLP-1 obesity coverage via demonstration starting July 2026 ([18]).
- CMS, BALANCE Model (Dec 2025) – Voluntary model combining GLP-1 access with lifestyle supports ([68]).
- CNBC, Trump announces deals with Eli Lilly, Novo Nordisk to slash weight loss drug prices (Nov 2025) ([17]).
- AJMC, Trump Announces Deals With Lilly, Novo for Lower Weight Loss Drug Prices (Nov 2025) ([22]).
- AJMC, FDA Approves Oral Semaglutide as First GLP-1 Pill for Weight Loss (Dec 2025) ([19]).
- AHIP, 2026 Will Bring Progress on Simplifying Prior Authorization (Jan 2026) ([15]).
- Health Affairs/KFF, Health Benefits In 2025: Large Employers Increase Coverage Of GLP-1s For Weight Loss (2025) ([26]).
- FDA, FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize (Feb 2025) ([62]).
- Prime Therapeutics, GLP-1 Pipeline Update: February 2026 ([47]).
- CoverMyMeds, AI Boosts Prior Authorization Determinations at Scale (2025) ([83]).
- Additional stakeholders’ whitepapers and professional society recommendations (see inline citations).
Each numbered reference above corresponds to the inline citation marks (e.g. ([7])) throughout the report. All cited information is from reputable news reports, peer-reviewed articles, or official industry sources.
Sources / 83
Need Expert Guidance on This Topic?
Let's discuss how IntuitionLabs can help you navigate the challenges covered in this article.
I'm Adrien Laurent, Founder & CEO of IntuitionLabs. With 25+ years of experience in enterprise software development, I specialize in creating custom AI solutions for the pharmaceutical and life science industries.
The information contained in this document is provided for educational and informational purposes only. We make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability, or availability of the information contained herein. Any reliance you place on such information is strictly at your own risk. In no event will IntuitionLabs.ai or its representatives be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from the use of information presented in this document. This document may contain content generated with the assistance of artificial intelligence technologies. AI-generated content may contain errors, omissions, or inaccuracies. Readers are advised to independently verify any critical information before acting upon it. All product names, logos, brands, trademarks, and registered trademarks mentioned in this document are the property of their respective owners. All company, product, and service names used in this document are for identification purposes only. Use of these names, logos, trademarks, and brands does not imply endorsement by the respective trademark holders. IntuitionLabs.ai is an AI software development company specializing in helping life-science companies implement and leverage artificial intelligence solutions. Founded in 2023 by Adrien Laurent and based in San Jose, California. This document does not constitute professional or legal advice. For specific guidance related to your business needs, please consult with appropriate qualified professionals.
Related Articles
ePA Explained: NCPDP SCRIPT & Surescripts Prior Authorization
Learn how the NCPDP SCRIPT standard enables electronic prior authorization (ePA). Explore the technical workflow, Surescripts CompletEPA, CMS-0057-F requirements, AI automation, and FHIR-based PA APIs shaping 2026-2028 compliance.
Pharmacy vs. Medical Benefit Explained: GLP-1 Coverage
Learn the key differences between pharmacy vs. medical benefit and how this structure impacts insurance coverage for GLP-1 drugs for diabetes and obesity, including the 2025–2026 Medicare BALANCE Model, manufacturer price cuts, and employer coverage trends.
GLP-1 Drugs: A Complete History of Incretin-Based Therapy
Learn the complete history of GLP-1 drugs from the incretin effect to 2026 breakthroughs. Covers exenatide, semaglutide, tirzepatide, oral Wegovy, retatrutide, CagriSema, and the evolution from diabetes to obesity treatment.